Presynaptic Imaging in Major Depressive Episodes After COVID-19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-75
SponsorCentre for Addiction and Mental Health
About this trial
The goal of this observational study focuses on understanding and addressing a subset of persistent neuropsychiatric symptoms occurring within 3 months after mild to moderate COVID-19 infection (COVID-DNP). COVID-DNP encompasses major depressive episodes (MDE) with or without additional neuropsychiatric symptoms.
Eligibility criteria
Qualifiers
New onset MDE within 3 months after mild or moderate COVID-19, with MDE verified by the research version SCID for DSM 5. See "Positive COVID-19 diagnosis" listed after inclusion/
Disqualifiers
Age 18 to 75.
Good general physical health with no active medical conditions based on self-report (except migraine or PASC).
Use of antidepressants in the previous month (6 weeks for fluoxetine).
Use of stimulant medication affecting dopamine release in the previous month
Trial design
Treatments tested in this trial
- [11C]DTBZ PET scan
- [18F]SDM8 PET scan
- MRI scan
Treatment groups
90 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov